IHS Announces CE Mark Certification for Proprietary Syringe Infusion System
Innovative Health Sciences, LLC (“IHS” or the “Company”) announced today that they have received ISO 13485 quality management system and CE mark certification for the Insignis™ Syringe Infusion System. The CE mark, abbreviated for European Conformity ("Conformité Européene"), enables IHS to sell the system throughout the European Union.
The Insignis™ Syringe Infusion System is the first combination of intravenous and subcutaneous non-electric infusion pump created for use with a selectable rate flow controller, the IV Controller and the OneSett™.
The transformative Insignis™ System for intravenous administration answers the world-wide need for a portable, non-electric, versatile, cost-effective, and intuitive infusion pump to accurately deliver medications from KVO up to 250ml/hr with a direct reading selectable rate flow controller.
For subcutaneous applications, the OneSett™ consists of a selectable rate flow controller attached directly to a subcutaneous needle set (1-4 leg configuration offering), which enables the user to select the flow rate (from 10ml – 60ml) with the turn of a dial. The flow rate indicated on the dial is delivered to each needle site – no calculation required!
The Insignis™ syringe pump is much less costly, offered at 139 Euro, and when considering the cost of the separate pieces of the ancillary supplies (needle sets, flow control tubings, and flow controller), the OneSett™ is also lower cost per infusion – even before considering the savings incurred from fewer stocking parts.
The IHS infusion system addresses nearly every infusion therapy need and can support intermittent, “pause” dosing, ideal for lengthy low-volume hospital infusions. “The IHS system represents a paradigm shift in simplicity, excellence, cost effectiveness, usability and patient-centered design,” says Andrew Sealfon, IHS founder, Chairman, and CTO.
Sealfon is a forty-year investor, innovator, and executive of the medical device industry. Inventor and founder of Repro-Med Systems, Inc. (KORU Medical Systems), Sealfon served as its President, Chairman of the Board, and Chief Executive Officer from September 1982 until his termination (July 25, 2018).
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion.
Forward-Looking Statements
The statements contained herein are not guaranteed of future performance and undue reliance should not be placed on them. Such Forward-Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward-Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005313/en/
Contact information
FMI: Tyler Kilcoin
845-610-5665
tkilcoin@innohealthsci.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADM Accelerates Growth of Leading Global Alternative Protein Platform with Planned Acquisition of Sojaprotein26.7.2021 14:05:00 CEST | Press release
Global nutrition leader ADM (NYSE: ADM) announced today that it has reached an agreement to acquire Sojaprotein, a leading European provider of non-GMO soy ingredients. Established in 1977, Serbia-based Sojaprotein has sales into 65 countries, offering a wide array of non-GMO vegetable protein ingredients for an extensive list of European and global customers in the meat alternative, confectionary, protein bar, pharmaceutical, pet food, and animal feed segments. The company had more than $100 million in sales in 2020. “Thirty years ago, ADM invented the soy vegetable burger, giving rise to the plant-based protein segment. Today, alternative proteins represents one of our core growth platforms, and as this $10 billion global industry grows to $30 billion over the next decade, we are investing to expand our unparalleled capabilities,” said Leticia Gonçalves, ADM’s president of Global Foods. “The addition of Sojaprotein – the largest producer of plant-based protein in southern Europe – ad
ABB to Divest Mechanical Power Transmission Division (Dodge) to RBC Bearings for $2.9 Billion26.7.2021 13:30:00 CEST | Press release
ABB today announced it has signed a definitive agreement to divest its Mechanical Power Transmission division (Dodge) to RBC Bearings Incorporated (Nasdaq: ROLL), for $2.9 billion in cash. The transaction will create a leading manufacturer of highly engineered, performance-critical bearings and motion control components. The transaction is expected to be completed by the end of the year 2021, subject to customary closing conditions, including regulatory review. For more than 140 years, the Dodge business has been a leader in the design, production, and marketing of mounted bearings, enclosed gearing, and power transmission components. It offers one of the broadest portfolios of mechanical power transmission products in the market, selling to industries such as surface mining, aggregates & cement, warehousing and food & beverage. Dodge has roughly 1,500 employees worldwide and achieved revenues of approximately $600 million for the last twelve months ending June 30, 2021, of which more
CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba ® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multi-drug resistant tuberculosis26.7.2021 12:00:00 CEST | Press release
Otsuka Novel Products GmbH (ONPG), a subsidiary of Otsuka Pharmaceutical Co., Ltd., is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of Deltyba 25 mg dispersible tablets (delamanid) for use as part of an appropriate combination regimen for pulmonary MDR-TB in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The current World Health Organization Global TB Report estimates that 1.2 million children (0-14 years of age) fell ill with TB in 2019.2 According to a scientific publication, every year approximately 25,000-32,000 children world-wide fall ill with MDR-TB. Of these, only a few are diagnosed and treated successfully and approximately 21% of children with MDR-TB are likely to die.1 New global targets set at the UN’s High Level Meeting on TB in 2018 inclu
First-of-Its-Kind “Pathways to Dairy Net Zero” Initiative to Raise Climate Ambition for the Global Dairy Sector26.7.2021 11:00:00 CEST | Press release
Afirst-of-its-kind Pathways to Dairy Net Zero initiative is being developed to accelerate climate change action throughout the global dairy sector. Announced today at the United Nations (UN) Food Systems Pre-Summit, the climate effort will be unlike any other in agriculture in terms of size, breadth, and scope. “The global dairy sector is creating this ground-breaking initiative to help speed climate action already underway, while continuing to provide livelihoods for a billion people and important nutrition for six billion people,” said Donald Moore, Executive Director at the Global Dairy Platform. A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop methodologies, tools and pathways that work for every dairy system. Pathways to Dairy Net Zero will officially launch during the UN Food Systems Summit in September and aims to generate commitments at the UN Climate C
Santen and IAPB Taking Action to Implement the First Ever UN General Assembly Resolution Recognizing the Link Between Eye Health and Sustainable Development26.7.2021 09:00:00 CEST | Press release
Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services. Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We
HKTDC Twin Jewellery Events Open in Hong Kong26.7.2021 08:52:00 CEST | Press release
The HKTDCHong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem & Pearl Show, opened on 25 July at the Hong Kong Convention and Exhibition Centre (HKCEC) and will run until 29 July. The twin shows are the first two physical trade fairs to be staged by the Hong Kong Trade Development Council (HKTDC), since the pandemic began and are being held in a hybrid format for the first time, with both physical and online exhibitions. The online show will run until 5 August to help global jewellers capture business opportunities as the pandemic continues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210725005042/en/ The HKTDC Hong Kong International Jewellery Show and the HKTDC Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council (HKTDC), take place on 25-29 July 2021 at the Hong Kong Convention and Exhibition Centre (HKCEC), helping jewellers capture bu
Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth26.7.2021 08:30:00 CEST | Press release
After nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH). Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210725005005/en/ Sarika – the first woman to receive heat-stable carbetocin, with her husband, newborn son and the first doctor to administer, Dr Yeshita V Pujar, Karnataka, India (Photo: Business Wire) This major maternal health milestone has been eagerly awaited since the publication of the CHAMPION (Carbetocin HAeMorrhage PreventION) trial results in 20182 - a study led by the World Health Organization (WHO) as part of a collaboration with MSD for Mothers* and